2022
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clinical Infectious Diseases 2022, 76: e342-e349. PMID: 35653428, PMCID: PMC9214014, DOI: 10.1093/cid/ciac443.Peer-Reviewed Original ResearchConceptsSevere COVID-19COVID-19 vaccination statusVaccination statusHazard ratioCOVID-19Severe acute respiratory syndrome coronavirus 2High-risk patients trialModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Adjusted hazard ratioHigh-risk patientsTreatment of mildCox hazard regressionSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerEligible patientsOlder patientsRisk patientsHazards regressionCoronavirus 2Cardiovascular diseaseTime-dependent variables
2020
SOFA score and short-term mortality in acute decompensated heart failure
Elias A, Agbarieh R, Saliba W, Khoury J, Bahouth F, Nashashibi J, Azzam Z. SOFA score and short-term mortality in acute decompensated heart failure. Scientific Reports 2020, 10: 20802. PMID: 33257739, PMCID: PMC7705654, DOI: 10.1038/s41598-020-77967-2.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureSequential Organ Function Assessment (SOFA) scoreShort-term mortalityDecompensated heart failureSOFA scoreHigh-risk patientsHospital mortalityRisk patientsHeart failureLife-threatening conditionCurve (AUC) of receiverFirst hospitalizationPrimary diagnosisRisk scorePatientsMortalityAssessment scoresStrict monitoringExcellent scoresCharacteristic curveHospitalizationScoresGood predictive accuracyProper managementSepsis